Kite Pharma

Arcellx is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients with cancer and other incurable diseases. The company aims to enhance the safety, effectiveness, and accessibility of these therapies. Its lead product candidate, CART-ddBCMA, targets relapsed or refractory multiple myeloma and is currently undergoing a Phase 1 clinical study. This therapy has received multiple designations from the U.S. Food and Drug Administration, including Fast Track and Orphan Drug status. Additionally, Arcellx is advancing its controllable CAR-T therapy, ARC-SparX, through two clinical programs aimed at treating relapsed or refractory multiple myeloma and acute myeloid leukemia.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune conditions. Founded in 2015, Tmunity specializes in creating engineered T cells, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg), utilizing proprietary technologies to activate, expand, and genetically modify T cells sourced from peripheral blood, cord blood, and tumors. The company aims to harness the potential of T cells to provide personalized next-generation treatments and is advancing its clinical programs in various disease areas. Tmunity's team is comprised of experts in T-cell biology, regulatory affairs, and clinical development, with a strong track record in executing successful cell and gene therapy trials. Additionally, Tmunity has established a robust manufacturing platform that supports multi-center clinical studies across diverse therapeutic indications.

Arcellx is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients with cancer and other incurable diseases. The company aims to enhance the safety, effectiveness, and accessibility of these therapies. Its lead product candidate, CART-ddBCMA, targets relapsed or refractory multiple myeloma and is currently undergoing a Phase 1 clinical study. This therapy has received multiple designations from the U.S. Food and Drug Administration, including Fast Track and Orphan Drug status. Additionally, Arcellx is advancing its controllable CAR-T therapy, ARC-SparX, through two clinical programs aimed at treating relapsed or refractory multiple myeloma and acute myeloid leukemia.

AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies aimed at preventing and treating serious viral-associated diseases. The company's lead product, Viralym-M, targets multiple viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Additionally, AlloVir is advancing several product candidates through preclinical and clinical stages, such as ALVR106 for respiratory syncytial virus and influenza, ALVR109 for SARS-CoV-2, ALVR107 for hepatitis B, and ALVR108 for human herpesvirus-8. The company, originally founded in 2013 as ViraCyte, Inc., rebranded to AlloVir in May 2019 and is committed to addressing the urgent medical needs of patients with limited treatment options for viral diseases.

Shoreline Biosciences, Inc. is a biotechnology company based in La Jolla, California, founded in 2020. The company specializes in developing cell-based immunotherapies aimed at treating seriously ill patients. Shoreline utilizes a proprietary technology platform that focuses on induced pluripotent stem cell (iPSC) differentiation and the genetic programming of the IL-15/CISH pathway. This approach enhances the metabolic fitness and persistence of engineered natural killer (NK) cells, thereby improving their anti-cancer activity. In addition to NK cells, Shoreline is also advancing the development of iPSC-derived macrophages for oncology and disease-modifying therapies. The company's innovative solutions aim to provide healthcare professionals with effective and cost-efficient treatment options for patients facing serious health challenges.

Orna Therapeutics, founded in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts, is a biotechnology company specializing in the development of fully engineered circular RNA therapeutics. The company's proprietary platform combines innovative technology to create circular RNAs that drive protein expression, coupled with validated delivery solutions. This approach aims to simplify production, enhance formula stability, and improve protein expression for treating various diseases.

Shoreline Biosciences, Inc. is a biotechnology company based in La Jolla, California, founded in 2020. The company specializes in developing cell-based immunotherapies aimed at treating seriously ill patients. Shoreline utilizes a proprietary technology platform that focuses on induced pluripotent stem cell (iPSC) differentiation and the genetic programming of the IL-15/CISH pathway. This approach enhances the metabolic fitness and persistence of engineered natural killer (NK) cells, thereby improving their anti-cancer activity. In addition to NK cells, Shoreline is also advancing the development of iPSC-derived macrophages for oncology and disease-modifying therapies. The company's innovative solutions aim to provide healthcare professionals with effective and cost-efficient treatment options for patients facing serious health challenges.

Fosun Kite Biotechnology is a joint venture between Shanghai Fosun Pharmaceutical and Kite Pharma, dedicated to the development of immune cell therapy products aimed at treating cancer. The company focuses on innovative pharmaceuticals, particularly through its research into axicabtagene ciloleucel and kite-439. These therapies are designed for the treatment of B-cell lymphomas and leukemias, with an emphasis on delivering high-quality medicines to the medical industry.

Vineti, Inc. is a technology company that specializes in developing solutions for the therapeutic delivery of personalized medicine, particularly focusing on cell and gene therapies. Founded in 2016 and headquartered in San Francisco, California, with additional offices in Bethesda, Maryland, and Yerevan, Armenia, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform streamlines and automates patient-centric supply chains, facilitating the efficient management of operations, manufacturing, quality control, and regulatory compliance for advanced therapies, including CAR-T cell therapies for late-stage cancer. Vineti's solutions aim to enhance patient access to life-saving treatments while addressing the challenges faced by patients, healthcare providers, pharmaceutical companies, and regulators in the commercialization of personalized medicine. By providing tools for supply chain orchestration and maintaining an audit trail for the handling of cell products, Vineti positions itself as a critical player in the evolving landscape of personalized therapeutics.

HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.

Gadeta is a research and development company focused on creating immunotherapies for cancer treatment. The company has developed a technology platform utilizing combinatorial T cell receptor exchange (CTE) to optimize gamma delta (γδ) T-cell receptors (TCRs), which exhibit enhanced anti-cancer activity. Gadeta's primary product, T Cells Engineered To Express A Defined Gamma Delta TCR (TEGs), demonstrates significant therapeutic potential against both hematological and solid tumors. By employing high-affinity γδ TCRs on αβ T cells, Gadeta's approach aims to improve the proliferation capacity of these T cells, thereby providing healthcare institutions and cancer patients with innovative solutions to combat advanced malignancies.

Cell Design Labs, Inc. is a biotherapeutics company based in San Francisco, California, focused on developing innovative cell-based therapies for cancer and other serious diseases. Established in 2015, the company aims to harness the immune system's capabilities to create advanced treatments that offer improved power, precision, safety, and durability. Cell Design Labs specializes in disruptive T cell receptor therapies, which modify the body's immune cells to specifically recognize and eliminate malignant cells. This approach enables researchers to efficiently develop effective cell-based therapies that address some of the most challenging medical conditions. The company operates as a subsidiary of Gilead Sciences, Inc.